PacBio: Financial Floor Found – Medical Relevance Explodes

We last highlighted PacBio here on October 9, 2025. Despite decreased revenues and an expected record loss for the entire year 2025, forecasts indicated a financial turnaround starting in 2026. The hope was fueled not only by a solid cash position to cover debts but also by new strategic partnerships (such as with seqWell) and participation in an $80 million aging research study. Our conclusion to closely monitor the stock has proven correct: since then, the price has increased by 48%, while the company provided further reasons for optimism in January....